Company: BLTE
Filing Date: 2025-10-22
Form Type: F-3ASR
Source: 0001104659-25-101403
Chunk: 1

Company: BELITE BIO, INC
Filing Date: 2025-10-22
Form: F-3ASR
Chunk 1
---
 registration statement number of the earlier effective registration statement for the same offering. ☐ If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒ If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. Emerging growth company ☒ If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

TABLE OF CONTENTS

### PROSPECTUS

#### Belite Bio, Inc
<div align='center'>**1,953,124 American Depositary Shares representing 1,953,124 Ordinary Shares 
 Up to 1,953,124 American Depositary Shares representing 1,953,124 Ordinary Shares**</div>

#### issuable upon exercise of the Warrants
**This prospectus relates to the resale by the Selling Shareholders, as defined in the section titled “Selling Shareholders” below, of (i) up to an aggregate of 1,953,124 of our American depositary shares, or ADSs, representing 1,953,124 of our ordinary shares, par value US$0.0001 per share; and (ii) up to an aggregate of 1,953,124 of our ADSs representing 1,953,124 of our ordinary shares issuable by us to the Selling Shareholders upon the exercise by the Selling Shareholders of warrants that were previously issued to the Selling Shareholders in a private placement completed on September 9, 2025 (the “2025 September PIPE”) under certain securities purchase agreements dated September 8, 2025 (the “2025 September Securities Purchase Agreements”). Throughout this prospectus